Abstract Metzincins and functionally related genes play important roles in extracellular matrix remodeling both in healthy and fibrotic conditions. We recently presented a transcriptomic classifier consisting of 19 metzincins and related
Introduction
Fibrosis is a tissue-repair response to chronic and severe tissue injury, including chronic exposure to pathogens or toxins like cigarette smoke, asbestos, and alcohol. A major cause of long-term organ failure, fibrosis is currently irreversible and is hence subject to extensive research efforts. Tissue repair is a delicately balanced process of sequential interplay of secretion of growth factors, chemokines, the deposition and degradation of extracellular matrix (ECM), angiogenesis, apoptosis, and eventually either resolution of the injury through regeneration, or healing accompanied by scar formation. Disruption or deregulation of any of those processes, or persistent tissue injury, leads to abnormal tissue repair, termed fibrosis, which consequently results in sclerosis. The role of inflammation as a trigger of normal and abnormal tissue repair cascades is still under debate [2, 3] .
A common denominator of fibrotic wound repair is excessive deposition, reorganization, and remodeling of extracellular matrix (ECM). ECM remodeling is mediated by a number of genes and pathways, among others by the superfamily metzincins, which are zinc-dependent metal-loproteases. Metzincins can be subdivided into groups of proteins with a disintegrin and metalloprotease domain (ADAM), ADAM with thrombospondin motif (ADAMTS), serralysins, papalysins, and matrix metalloproteases (MMP). All have been shown to play roles during fibrogenesis [4, 5] . As we have previously reported, we have extended the group of metzincins and generated a gene set termed MARGS (metzincins and related genes). We included transcription factors, activators, inhibitors and substrates, and cell-surface and cytoplasmic proteins which regulate the functions of metzincins [1] . The list of 191 MARGS includes genes with roles in epithelial cell damage (e.g., fibrin, fibronectin, collagens), fibroblast proliferation (e.g., TGF, TNF, SERPINE), basement membrane remodeling (e.g., MMP2, MMP9), fibroblast foci formation (e.g., TIMP1, TIMP2), as well as angiogenesis (e.g., VEGF) and impaired re-epithelialization (e.g., MMPs/TIMPs) (Supplementary Table TS1 ). Thus, MARGS are representative of important phases of normal and fibrotic tissue repair.
Timely diagnosis of fibrosis through molecular markers and classical clinical parameters may be an invaluable indication for treatment adjustment prior to the development of irreversible sclerosis.
We have previously demonstrated that gene expression of MARGS correlates at large with progression of human interstitial fibrosis/tubular atrophy (IF/TA) in renal allograft biopsies [1] . We also showed in three independent microarray datasets that a gene panel consisting of 19 MARGS could be used to classify human renal biopsies with and without IF/TA.
Here we extend those findings and test the performance of the IF/TA gene expression classifier in human fibrosis of various etiologies in five different organs. Using publically available microarray datasets, we demonstrate first that MARGS indeed are differentially expressed under conditions of fibrosis in aging kidney, heart failure, liver cirrhosis, idiopathic pulmonary fibrosis, and pancreatitis. We confirm these data by TaqMan quantitative RT-PCR in independent etiology-matched patient samples, and finally show in support of our hypothesis good diagnostic value of the MARGS-panel classifier in the microarray datasets.
Materials and methods

Datasets
An overview of the microarray datasets is shown in Table 1 . The expression data for the kidney dataset was downloaded from http://genome-www5.stanford.edu [6] . Gene expression datasets for heart and lung were downloaded from Gene Expression Omnibus, http://www.ncbi.nlm.nih.gov/geo, Heart: GSE5406 [7] , Lung: GSE10667 [1] . Liver and pancreas data were provided by the authors [9, 10] .
Microarray analysis
Gene expression analysis was performed in Partek Genomics Suite 6.5 (http://www.Partek.com) and R (http://www. bioconductor.org). Where non-processed data were available, datasets were quantile normalized with RMA background correction and median polish. The manuscript is based on the assumption that genes are appropriately matched to common identifiers across platforms to achieve comparability of data. We used Entrez Gene IDs for this purpose, as they appear to be relatively stable over time (J.S. Marron, personal observation). Expression signal intensities for features mapping to the same Entrez GeneID were averaged. Pseudogenes and all features on the platforms without Entrez Gene ID were excluded.
Expression filters were applied to all datasets, except those with ratio measures. Only genes with signal intensity measurements of at least 6.5 in log 2 scale in a number of samples corresponding to 75% in the smallest analysis group were considered further. Differentially expressed genes were identified by ANOVA after application of a gene list filter. No expression filter was applied for testing the MARGS classifier. Receiver operator characteristic (ROC) curves and calculation of the AUC was done with the R package ROCR [11] .
Classifier algorithm was linear discriminant analysis (LDA) with leave-one-out cross-validation.
Patients for confirmation analyses
For confirmation of microarray results, we utilized archival formalin fixed paraffin embedded (FFPE) pancreas, lung, liver, kidney, and heart tissue from the Institute of Pathology, University of Berne, Switzerland. Fibrotic and non-fibrotic tissue specimens from a total of 50 patients were utilized ( Table 2 ). Great care was taken to select the cases with best match to the histological diagnosis of cases used for microarray data analyses [6] [7] [8] [9] [10] . All patients remained anonymized except for age and gender, and all studies were approved by the local ethics commission. [12] . For the heart analysis, we used microarray data from 194 samples from advanced systolic heart failure and from 16 non-failing hearts [7] . Heart failure patients suffered either from ischemic (n=86) or idiopathic dilated (n=108) cardiomyopathy. This difference was neglected in the present analysis. The lung analysis comprised samples from 23 patients with interstitial pulmonary fibrosis (IPF) and eight with acute exacerbation of IPF (IPF-AEx) [8] . For the purpose of our study, these two groups were combined to one and compared to 16 samples from patients with normal lung histology. Samples for the liver analysis were selected from the healthy control group and from those patients with an adjusted morphologic fibrosis index (MFI) score ≥10 (average F-score for this group is 3.4). The adjusted MFI is the mean MFI determined from nine section images, adjusted by a factor of 1.13, which corrects for a mean MFI of 1.13 in samples of healthy control patients [9] . The majority of the fibrosis samples originated from patients with hepatocellular carcinoma, most of which were positive for hepatitis C virus (HCV) antibody. Finally, the pancreas dataset consisted of samples from patients with chronic pancreatitis (n=5), pancreatic adenocarcinoma (n= 10), and five normal pancreas samples [10] . Chronic pancreatitis and adenocarcinoma samples were grouped into one. Due to the different platforms and population of features on the arrays, different numbers of MARGS are represented on the platforms. For instance, the kidney cortex dataset with HG-U133A and B included 175 MARGS, while 100 MARGS were represented on the platform of the pancreas dataset. This has implications for the comparison of differentially expressed MARGS, as we do not have information on the expression of many MARGS on some of the platforms (see below).
The initial analytical steps had to be adjusted to each dataset. The kidney cortex data where distributed on HG-U133A and HG-U133B arrays. We used only array pairs which had been generated from the same patient RNA. As 99 probesets are shared between both array types, data were merged into one matrix by mean adjustment of the expression values of those probesets. The signal intensities of the pancreas dataset were floored to a minimum value of 10 and log 2 transformed. The liver dataset had been Lowess normalized. As the samples had been split into training and test set by the authors, we treated the technical effect by mean adjustment. Sample A47, adjusted morphologic fibrosis index (MFI) 17.43, was excluded in the further analysis due outlier-like behavior which could not be explained with the data at hand.
Differentially expressed MARGS Figure 1 shows principal component analysis (PCA) of differentially expressed MARGS which pass the expression filter (see "Materials and methods") and had a false discovery rate q-value qFDR <0.01 in each dataset separately. The number of MARGS with differential expression naturally is dependent on the significance of biological/clinical differences between the sample groups, but also influenced by the platform design, i.e., how many MARGS are represented on the platforms. In kidney cortex, 59 of overall 175 MARGS on the platform pass our filter criteria and only four of a total of 179 MARGS in liver.
It is obvious that differentially expressed MARGS are sufficient in the kidney cortex, liver, and pancreas dataset to separate fibrosis samples from control samples. The PCA of the heart samples showed some overlap between normal and fibrotic samples due to the inclusion of samples with mild to very mild grades of fibrosis. In lung, there are three samples of the control group, GSM269754, GSM269762, and GSM269757, which display extreme behavior with respect to MARGS expression and tend to be placed close to the fibrosis group. Technical or biological/clinical reasons not known to us may account for this.
Five-way Venn diagram
Uniformly deregulated genes in kidney cortex, heart, liver, lung, and pancreas fibrosis were identified by Venn analyses, comparing all deregulated MARGS in each organ fibrosis dataset having a qFDR <0.1 (Fibrosis vs. Control) after expression filter. In this analysis, we chose a larger qFDR threshold to compensate for the-in relation to the other datasets-larger qFDR values in the liver dataset. We had also noticed that the set of MARGS with smallest qFDR in liver are different from the set of MARGS with smallest qFDR in the other datasets. To recruit a sufficient number of MARGS as candidates for qRT-PCR confirma-tion from this analysis, we applied a more permissive qFDR cutoff.
Eighty-five MARGS in kidney cortex were compared to 40 MARGS in heart fibrosis, 48 MARGS in liver fibrosis, 110 MARGS in lung fibrosis, and 78 MARGS in pancreas fibrosis (Fig. 2a) . The set union formed by all five datasets consisted of tissue inhibitor of metalloproteinase 1 (TIMP1) and hypoxia upregulated protein 1 (HYOU1). The analyses revealed that 14 MARGS were only deregulated in kidney fibrosis, whereas 25 genes were identified to be solely deregulated in lung fibrosis, two genes in heart fibrosis, seven genes in liver fibrosis, and 11 in pancreas fibrosis (Fig. 2b) . Nine genes were differentially expressed in kidney cortex, liver, lung, heart, and pancreas, but not in liver. These genes were collagen, type I, alpha 1 (COL1A1), collagen type I, alpha 2 (COL1A2), collagen type III, alpha 1 (COL3A1), matrix metallopeptidase 2 (MMP2), secreted protein, acidic, cysteine-rich (SPARC), thrombospondin 2 (THBS2), thrombospondin 3 (THBS3), TIMP metallopeptidase inhibitor 3 (TIMP3), and vascular endothelial growth factor C (VEGFC). Genes belonging to the family of thrombospondins (THBS) were deregulated in each organ. THBS2, previously identified as IF/TA marker in kidney allograft biopsies (1), was deregulated in fibrosis of all organs but liver. Here, the family member THBS1 was deregulated. MMP7, besides THBS2, another candidate as IF/TA marker, showed deregulation in kidney, pancreas, and lung fibrosis but not in liver and heart (Fig. 2b) .
Cross-organ deregulated MARGS are confirmed in independent patient samples From the list of 11 MARGS which were differentially expressed in all organs or all organs but liver, and from results of our previous studies [1] , we selected seven MARGS for confirmation analyses: THBS2, TIMP1, COL1A2, COL3A1, HYOU1, MMP2, and MMP7. As control genes served two genes which had a coefficient of variation less than 7.5 % in each dataset, heterogeneous nuclear ribonucleoprotein U (HNRNPU) and paxillin (PXN). Archival biopsy specimens of patients with which encompass 95% of the samples per group were added. Criterion for differential expression is a qFDR <0.01 after expression filter (see "Materials and methods"). Number before bracket is the number of MARGS genes with qFDR <0.01, the number inside the bracket is the number of MARGS represented on the array platform matched histological diagnosis to microarrays served as RNA source (Table 2 , "Materials and methods").
Of 28 confirmation tests in kidney cortex, heart, lung, and pancreas, 25 (89%) confirmed the direction of expression changes observed in the microarray datasets (Fig. 3a) . Of the three which could not be confirmed, MMP7 was expressed at low levels in the heart microarray dataset and had not passed the qFDR filter. The other two tests which failed were COL3A1 in kidney cortex and TIMP1 in pancreas.
THBS2 and MMP2 were upregulated in fibrosis of all organs. HYOU1 showed increased expression in fibrosis of kidney, liver, and lung, and showed decreased expression in heart and pancreas fibrosis. TIMP1 was upregulated in all organs except heart (Fig. 3a) . The same pattern was observed for MMP7 with decreased expression only in heart fibrosis. Highest expression values in heart fibrosis were observed for COL3A1 and COL1A2 (fc vs. Normal 0.73 and 0.61, log 2 scale, respectively). All candidate MARGS showed increased expression in pancreas, liver, and lung fibrosis; only in heart and kidney fibrosis decreased expression was identified for certain selected MARGS when compared to healthy tissue (Fig. 3a) . As shown in Fig. 3b , TaqMan qRT-PCR data lead to cluster formation of in-house samples according to diagnosis in a PCA in all five tissues.
Interestingly, out of seven liver tests, only two could be confirmed, MMP7 and MMP2, where MMP2 had a small fold change in the microarray dataset (0.03, log 2 scale). All candidate MARGS were upregulated in liver fibrosis in the in-house samples, while five of seven were downregulated in the microarray dataset.
Classifier analysis
We have previously shown in an in-house gene expression microarray dataset as well as other published datasets that a classifier model consisting of 19 MARGS in combination with Linear Discriminant Analysis decision algorithm can discriminate human renal allograft biopsies with interstitial fibrosis and tubular atrophy (IF/TA) from those without [1] . To test our hypothesis, that the same classifier panel could discriminate fibrosis of different etiology from non-fibrosis in non-transplant setting, we applied the published classifier to the microarray datasets, including internal leave-one-out cross-validation.
Without expression filter, the MARGS classifier list was applied to the datasets, along with the algorithm Linear Discriminant Analysis and full leave-one-out internal crossvalidation. As not all MARGS of the classifier panel were represented on each platform, gene subsets of the classifier had to be used in some instances (Table 3) . In kidney cortex, 18 of the 19 classifier MARGS could be used, in heart 15, in lung and liver all 19, and in pancreas 10 (Supplementary Table TS2 ). As can be seen in Table 3 , the performance estimate "area under the ROC curve" (AUC) for the binary prediction of "fibrotic" or "healthy" exceeded 0.78 in each dataset. The mean AUC was 0.872. The mean accuracy was 88%. The best classification rate was achieved in kidney cortex, where all samples were correctly classified; the lowest performance was measured with the liver dataset where the correct classification rate was 72.7% (AUC=0.786). The significance of the AUC was estimated by bootstrapping (seed=100,000). A lower limit of the 95th Fig. 2 Differentially expressed MARGS in fibrosis datasets. a Fiveway Venn diagram identifies two MARGS genes which are differentially expressed in all five datasets. Nine additional MARGS are differentially expressed in all datasets but liver (shaded fields). Criterion for differential expression is a qFDR <0.1 and passing an expression filter (see "Materials and methods"). b Gene lists from Venn diagram. Genes which were selected for confirmation analyses are underlined. In addition, MMP7 was selected based on previous findings (see main text). MMP7 was differentially expressed in kidney, lung, and pancreas microarray datasets (not shown) Fig. 3 TaqMan RT-PCR confirmation of microarray data in independent sample sets. a TaqMan qRT-PCR confirmation of seven MARGS genes in five tissues. In kidney, heart, lung, and pancreas, 89% of the tests successfully confirmed the direction of expression changes. In liver, only two of seven tests were successful. TaqMan qRT-PCR: *p<0.1, **p<0.05; microarray: *qFDR value<0.1, qFDR value<0.05. b Principal component analysis of normalized TaqMan qRT-PCR values of seven MARGS. In an unsupervised analysis, the expression values of the genes separate the tissue samples in each comparison by diagnosis. Each sphere represents one sample. For visualization purposes, ellipsoids which encompass 95% of the samples per group were added percentile confidence interval larger than 0.5 indicates that the model performance is significantly better than random. This is the case in all analyses. A chi-square p value <0.5 indicates a significant dependence of the actual and the predicted values. In all tests, the chi-square p value is smaller than 0.5.
Next we integrated all five datasets across tissue and platform to obtain a set with 265 fibrosis samples and 65 control samples (Table 3) . Due to the integration of the pancreas dataset, only 10 MARGS genes could be used in this approach: CD44, THBS2, VEGFA, PLG, TNFAIP3, LAMB1, TNFSF10, COL3A1, THBS1, and MGP. Despite these limitations, the classifier performance reached a significant AUC of 0.82 and an accuracy of 88%.
Discussion
Genes comprising the MARGS gene set are known to be involved in remodeling of ECM under healthy and disease conditions [13] [14] [15] [16] . It is therefore conceivable that they play important roles in fibrotic/sclerotic conditions in organs, which may result in response to tissue injury, or as progression of age. Along those lines, differential expression of hypoxia-regulated genes, such as HYOU1 (hypoxia up-regulated 1), HIF1-target gene TIMP1 in all datasets, and THBS2, MMPs and collagens I and III in all but the liver microarray dataset are in correspondence with earlier findings which showed an involvement of hypoxia in fibrosis (kidney [17, 18] , pancreas [19] , lung [20, 21] , heart [22] [23] [24] , liver [25] [26] [27] ).
We were able to validate the gene expression trends we saw in kidney, heart, lung, and pancreas in 89% (25 of 28 tests) of the TaqMan qRT-PCR tests using archival tissue specimens, which is an exceptionally high rate considering that all sample sets were completely independent. Confirmation results were unsatisfactory for the liver microarray data (Fig. 3a) , where five of seven tests failed to validate the microarray data, although the TaqMan data themselves were significantly different between healthy and fibrotic samples (Fig. 3a, b) . Compared to the datasets of the other organs, only few MARGS in the liver dataset had qFDR values <0.01 (Fig. 1) . In our own analysis of the liver microarray data, we observed similar trends of gene expression changes as the Utsunomiya group and confirm the importance of inflammatory genes in that dataset (not shown). We found that most MARGS were in fact underrepresented in the fibrosis group (not shown), while proinflammatory genes were largely overrepresented and correlated with the adjusted MFI fibrosis grade, as published [9] . Recently, the group of Takahara has shown in gene expression studies of fibrosis in HCV patients that ECM modulatory genes in general positively correlate with ACC accuracy, AUC area under the ROC curve the METAVIR F-score 1 through 4, and some genes had peak expression changes in fibrosis score 2 and 3 [28] . In accordance with these data, we observe similar trends in expression changes with MARGS ECM genes when we use the categorical average METAVIR F-score instead of the continuous adjusted MFI; however, the qFDR values for the individual genes increase (not shown). We do not obtain a better correlation of TaqMan qRT-PCR and microarray data in terms of trends of "over-and under-representation" when we use the METAVIR F-score annotation of the microarray data. We believe that the differences between the microarray data of Utsunomiya's group and the Inselspital TaqMan qRT-PCR data may reveal differences in etiology or be of other clinical or biological origin which was impossible to capture from the annotations at hand despite our efforts to match our patient groups as much as possible with the published samples. The increases in, e.g., MMP2 and collagens type I and III that we observe in TaqMan qRT-PCR data match well with published findings (see [29] for review). Separately, the two analyses revealed significant differences for MARGS between liver fibrosis and healthy groups, leading to a separation of the sample groups in PCA of the microarray data and of the TaqMan qRT-PCR data ( Figs. 1 and 3 , respectively). Let us consider two major valid methods of identifying molecular markers, e.g., gene expression panels in combination with a decision algorithm. One method, let us use the term "gene-to-biology-method", essentially employs testing of all features on a technology platform (such as microarrays) and then, once the feature panel has been identified, links to the biology and pathways underlying the studied disease. While in theory it is not given that genes, or generally speaking, features, of a classifier which has been identified in an unbiased way are involved in the disease biology, in practice many researchers and clinicians feel much more comfortable with the classifier panel if they do, as it is intuitively plausible [30] . In our studies, we have employed another method, a "biology-to-gene-method". We first considered the biology of the diseases or complications we were interested in, used literature searches and knowledge to assemble a list of genes which play important roles in that biology, and asked whether those genes could serve as the starting gene list to generate a classifier panel. Hence, we easily linked the biology of fibrosis, post-transplant or in other etiologies, with molecular markers (the MARGS).
We previously showed that a subset of MARGS can be used to discriminate human renal allograft biopsy samples with IF/TA from non-IF/TA samples [1] . In the present study, we demonstrate that the IF/TA MARGS transcriptomics classifier panel also classifies solid organ fibrotic conditions of human aging kidney, cardiac failure, hepatic cirrhosis, pulmonary fibrosis, and pancreatitis tissue samples with high accuracy, AUC, specificity, and sensitivity (the sensitivity for the liver dataset was exceptionally low and the reason remains uncertain). Our studies suggest that the MARGS classifier is a valid candidate for a crossplatform, cross-organ classifier of normal tissue vs. fibrotic conditions of different etiologies. Obvious next steps are the application of the classifier to blood sample gene expression data, to see whether a minimally invasive, easily applicable gene expression marker could accompany or outperform other minimally and non-invasive methods [31] [32] [33] [34] . Given that, e.g., plasma levels of TIMP1 protein have been found elevated in diastolic dysfunction [35] , transfer of our data to, for instance, peripheral blood appears promising. From a clinical perspective, the MARGS classifier may be used to detect fibrosis prior to the development of irreversible tissue sclerosis, and thus enhance organ preservation through treatment adjustment. The classifier should be tested for its ability to diagnose fibrosis at a very early time point, ideally before fibrosis is visible on tissue sections and therapy is still most effective. In this respect, it will be interesting to test the classifier for its ability to be utilized to monitor drug effects. Future work will tell if some of the genes present in the MARGS panel represent therapeutic targets.
